Gastroesophageal VaricesNCT04524650
Early Diagnosis of Oxaliplatin-induced Portal Hypertension
An observational study of Gastroesophageal Varices and Colorectal Cancer, run by Shanghai Zhongshan Hospital at 1 site in China.
Trial summary
Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer. However, hepatotoxicity is the potentially problematic adverse effect of oxaliplatin. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Gastroesophageal Varices, Colorectal Cancer, Received Oxaliplatin-based Chemotherapy
- What is being tested?
- the level of vWF
- How many people
- 370 participants
- Where
- 1 siteChina
- Study dates
- 31 Aug 2020to 30 Sep 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who had a history of colorectal cancer and received oxaliplatin-based chemotherapy
Who may be able to join
- Male or female patients aged 18-75
- Had a history of oxaliplatin-based chemotherapy for the treatment of colorectal cancer surgery;
Who cannot join
- Combined known etiologies of chronic liver disease, including hepatitis, primary biliary cirrhosis, schistosomiasis, and non-alcoholic fatty liver disease.
- With colorectal cancer required further anti-tumor treatment
Trial locations and contacts
1 site in 1 country.
China1 site
Department of Gastroenterology and Hepatology
Shanghai, Shanghai Municipality, 200032
About this study
Official title: Construction and Evaluation of the Early Identification for Oxaliplatin Induced Portal Hypertension
Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer. However, hepatotoxicity is the potentially problematic adverse effect of oxaliplatin. The pathological evaluation of non-tumoral liver from patients with advanced colorectal cancer undergoing neoadjuvant oxaliplatin-based treatment has provided histological evidence of hepatic sinusoidal injury. Oxaliplatin-induced sinusoidal injury can persist for more than 1 year after the completion of chemotherapy, and the increase in splenic volume may be a predictor of irreversible sinusoidal damage. In this current study, the investigators aim to evaluate the values of potential biomarkers in diagnosing patients with oxaliplatin-induced gastroesophageal varices after colorectal cancer surgery.
- Being tested
- the level of vWF
- Keywords
- portal hypertension, splenomegaly, colorectal carcinoma, oxaliplatin, hepatotoxicity
- Medical subject headings
- Colorectal Neoplasms, Hypertension, Portal, Splenomegaly
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
the level of vWFDiagnostic test
the peripheral level of vWF
| Study group | Role | What they receive |
|---|---|---|
| stage 0 | without liver function injury or splenomegaly Receives: Diagnostic Test: the level of vWF | |
| stage 1 | occurrence of liver function injury (ALT or AST > 2 ULN (upper limit of normal) Receives: Diagnostic Test: the level of vWF | |
| stage 2 | occurrence of splenomegaly or reduced platelet count (<150 X10^9/L) Receives: Diagnostic Test: the level of vWF | |
| stage 3 | occurrence of portal hypertension and/or gastroesophageal varices Receives: Diagnostic Test: the level of vWF |
What is being measured
The primary outcome is the main question the study is designed to answer.
the severity of portal hypertension
High portal pressure
Measured: 1 day (the same time as diagnosis)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2020
- Study start31 Aug 2020 (estimated)
- Primary completion31 Oct 2021 (estimated)
- Study completion30 Sep 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Gastroesophageal VaricesStudies of the same condition, open and under way.
- More trials run by Shanghai Zhongshan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 370 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Zhongshan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shiyao Chen, Shanghai Zhongshan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04524650
- Sponsor's protocol ID
- PLAEGV-DIA
- Status last verified
- Aug 2020
- First submitted
- 20 Aug 2020
- Last updated
- 28 Aug 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Huang X, Li F, Wang L, Xiao M, Ni L, Jiang S, Ji Y, Zhang C, Zhang W, Wang J, Chen S. Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer. Endoscopy. 2020 Sep;52(9):727-735. doi: 10.1055/a-1157-8611. Epub 2020 May 7.
PubMed 32380558Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006 Nov 1;24(31):4983-90. doi: 10.1200/JCO.2006.05.8156.
PubMed 17075116
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Construction and Evaluation of the Early Identification for Oxaliplatin Induced Portal Hypertension
- ClinicalTrials.gov ID
- NCT04524650
- Acronym / sponsor ID
- PLAEGV-DIA
- Keywords
- portal hypertension, splenomegaly, colorectal carcinoma, oxaliplatin, hepatotoxicity
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 370 participants (estimated)
- Lead sponsor
- Shanghai Zhongshan HospitalUniversity, hospital or other
- Study start
- 31 Aug 2020 (estimated)
- Primary completion
- 31 Oct 2021 (estimated)
- Study completion
- 30 Sep 2022 (estimated)
- First posted
- 24 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer. However, hepatotoxicity is the potentially problematic adverse effect of oxaliplatin. The pathological evaluation of non-tumoral liver from patients with advanced colorectal cancer undergoing neoadjuvant oxaliplatin-based treatment has provided histological evidence of hepatic sinusoidal injury. Oxaliplatin-induced sinusoidal injury can persist for more than 1 year after the completion of chemotherapy, and the increase in splenic volume may be a predictor of irreversible sinusoidal damage. In this current study, the investigators aim to evaluate the values of potential biomarkers in diagnosing patients with oxaliplatin-induced gastroesophageal varices after colorectal cancer surgery.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| stage 0 | – | Diagnostic Test: the level of vWFwithout liver function injury or splenomegaly |
| stage 1 | – | Diagnostic Test: the level of vWFoccurrence of liver function injury (ALT or AST > 2 ULN (upper limit of normal) |
| stage 2 | – | Diagnostic Test: the level of vWFoccurrence of splenomegaly or reduced platelet count (<150 X10^9/L) |
| stage 3 | – | Diagnostic Test: the level of vWFoccurrence of portal hypertension and/or gastroesophageal varices |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who had a history of colorectal cancer and received oxaliplatin-based chemotherapy
Key inclusion criteria (2 listed)
- Male or female patients aged 18-75
- Had a history of oxaliplatin-based chemotherapy for the treatment of colorectal cancer surgery;
Key exclusion criteria (2 listed)
- Combined known etiologies of chronic liver disease, including hepatitis, primary biliary cirrhosis, schistosomiasis, and non-alcoholic fatty liver disease.
- With colorectal cancer required further anti-tumor treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| the level of vWFthe peripheral level of vWF | Diagnostic test | stage 0, stage 1, stage 2, stage 3 |
Primary outcome
the severity of portal hypertension
Time frame: 1 day (the same time as diagnosis)
High portal pressure
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2020.
- Results publication: PubMed 32380558Huang X, Li F, Wang L, Xiao M, Ni L, Jiang S, Ji Y, Zhang C, Zhang W, Wang J, Chen S. Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer. Endoscopy. 2020 Sep;52(9):727-735. doi: 10.1055/a-1157-8611. Epub 2020 May 7.
- Results publication: PubMed 17075116Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006 Nov 1;24(31):4983-90. doi: 10.1200/JCO.2006.05.8156.
- Individual participant dataSharing planned: Undecided
Related trials for Gastroesophageal Varices
RecruitingObservational study
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
Liver Cirrhosis, Gastroesophageal Varices
Not yet recruiting
Mesenteric Vein Access for OPVT-Related Recurrent Variceal Bleeding: An Ambispective Cohort
Occlusive Portal Vein Thrombosis (OPVT), Cavernous Transformation of Portal Vein
Recruiting
Comparison of Underdilated Versus Standard TIPS in Preventing Variceal Rebleeding in Patients With Cirrhosis
Liver Cirrhosis, Gastroesophageal Varices Bleeding
Not yet recruiting
Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis
Liver Cirrhosis, Portal Hypertension
Not yet recruitingObservational study
Optimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding
Portal Hypertension, Gastroesophageal Varices Hemorrhage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastroesophageal Varices and Colorectal Cancer, run by Shanghai Zhongshan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Xiaoquan HUANG (008618801733835, huang.xiaoquan@zs-hospital.sh.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the severity of portal hypertension (time frame: 1 day (the same time as diagnosis)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04524650, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2020.